Alagebrium: Phase IIb delayed

ALT halted enrollment in the double-blind, placebo-controlled, U.S. Phase IIb SPECTRA trial due to preclinical toxicity in rats (see BioCentury, Jan. 3). The trial will continue in the patients alread...